UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Alzheimer's & dementia, 2016-02, Vol.12 (2), p.110-120

2016

Volltextzugriff (PDF)

Drug development in Alzheimer's disease: the path to 2025

Alzheimer's research & therapy, 2016-09, Vol.8 (1), p.39-39, Article 39

2016

Volltextzugriff (PDF)

On the path to 2025: understanding the Alzheimer's disease continuum

Alzheimer's research & therapy, 2017-08, Vol.9 (1), p.60-60, Article 60

2017

Volltextzugriff (PDF)

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN

Cephalalgia, 2019-07, Vol.39 (8), p.957-966

2019

Volltextzugriff (PDF)

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

BMC neurology, 2019-08, Vol.19 (1), p.191-8, Article 191

2019

Volltextzugriff (PDF)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies

Neurology and therapy, 2020-12, Vol.9 (2), p.459-471

2020

Volltextzugriff (PDF)

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study

Cephalalgia, 2021-03, Vol.41 (3), p.294-304

2021

Volltextzugriff (PDF)

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk

Clinical cancer research, 2006-09, Vol.12 (17), p.5242-5247

2006

Volltextzugriff (PDF)

Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study

The Journal of urology, 2016-03, Vol.195 (3), p.699-705

2016

Volltextzugriff (PDF)

Effects of Testosterone Level on Lower Urinary Tract Symptoms

American journal of men's health, 2016-09, Vol.10 (5), p.440-442

2016

Volltextzugriff (PDF)

Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study

Cephalalgia, 2022-01, Vol.42 (1), p.20-30

2022

Volltextzugriff (PDF)

Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant

Headache, 2020-09, Vol.60 (8), p.1793-1796

2020

Volltextzugriff (PDF)

Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials

Headache, 2019-07, Vol.59 (7), p.1052-1062

2019

Volltextzugriff (PDF)

The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings

Headache, 2020-01, Vol.60 (1), p.178-189

2020

Volltextzugriff (PDF)

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

Neurology. Clinical practice, 2023-04, Vol.13 (2), p.e200127-e200127

2023

Volltextzugriff (PDF)

Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial : Results of Subgroup Analyses by Age and Other Factors

Circulation (New York, N.Y.), 2009-02, Vol.119 (7), p.922-930

2009

Volltextzugriff (PDF)

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease

Stroke (1970), 2009-01, Vol.40 (1), p.147-155

2009

Volltextzugriff (PDF)

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

Breast cancer research and treatment, 2012-07, Vol.134 (1), p.299-306

2012

Volltextzugriff (PDF)

Alzheimer's disease progression by geographical region in a clinical trial setting

Alzheimer's research & therapy, 2015-06, Vol.7 (1), p.43-43, Article 43

2015

Volltextzugriff (PDF)

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials

Alzheimer's research & therapy, 2015-06, Vol.7 (1), p.39-39, Article 39

2015

Volltextzugriff (PDF)

Raloxifene use in clinical practice: efficacy and safety

Menopause (New York, N.Y.), 2009-03, Vol.16 (2), p.413

2009

Volltextzugriff (PDF)

Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass

Menopause (New York, N.Y.), 2012-01, Vol.19 (1), p.41

2012

Volltextzugriff (PDF)

Effect of Raloxifene on Cardiovascular Adverse Events in Postmenopausal Women With Osteoporosis

The American journal of cardiology, 2006-02, Vol.97 (4), p.520-527

2006

Volltextzugriff (PDF)

Cardiovascular effects of raloxifene: the arterial and venous systems

The American heart journal, 2004-05, Vol.147 (5), p.783-789

2004

Volltextzugriff (PDF)

Risk factors for breast cancer in older women : the relative contribution of bone mineral density and other established risk factors

Breast cancer research and treatment, 2007-04, Vol.102 (2), p.181-188

2007

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

ThemaGeneral & Internal Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Englisch
(49)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Humans
(25)
Female
(16)
Clinical Neurology
(14)
Middle Aged
(14)
Neurosciences & Neurology
(14)
Aged
(12)
Adult
(8)
Biological And Medical Sciences
(8)
Male
(8)
Medical Sciences
(8)
Treatment Outcome
(8)
Dentistry
(7)
Neurosciences
(7)
Osteoporosis
(7)
Raloxifene Hydrochloride - Therapeutic Use
(7)
Risk Factors
(7)
Selective Estrogen Receptor Modulators - Therapeutic Use
(7)
Breast Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Drug development in Alzheimer's disease: the path to 2025

On the path to 2025: understanding the Alzheimer's disease continuum

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk

Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study

Effects of Testosterone Level on Lower Urinary Tract Symptoms

Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study

Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant

Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials

The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial : Results of Subgroup Analyses by Age and Other Factors

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

Alzheimer's disease progression by geographical region in a clinical trial setting

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials

Raloxifene use in clinical practice: efficacy and safety

Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass

Effect of Raloxifene on Cardiovascular Adverse Events in Postmenopausal Women With Osteoporosis

Cardiovascular effects of raloxifene: the arterial and venous systems

Risk factors for breast cancer in older women : the relative contribution of bone mineral density and other established risk factors

Aktive Filter

Suchergebnisse filtern